AIM: To investigate the therapeutic efficacy of short-term, multiple daily dosing of intravenous interferon (IFN) in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. METHODS: IFN-beta was intravenously administered at a total dose of 102 million international units (MIU) over a period of 28 d in 26 patients positive for HBeAg and HBV-DNA. IFN-beta was administered at doses of 2 MIU and 1 MIU on d 1, 3 MIU twice daily from d 2 to d 7, and 1 MIU thrice daily from d 8 to d 28. Patients were followed up for 24 wk after the end of treatment. RESULTS: Six months after the end of the treatment, loss of HBV-DNA occurred in 13 (50.0%) of the 26 patients, loss of HBeAg in 9 (34.6%), development of anti-HBe in 10 (38.5%), HBeAg seroconversion in 8 (30.8%), and normalization of alanine aminotransferase (ALT) levels in 11 (42.0%). CONCLUSION: This 4-wk long IFN-beta therapy, which was much shorter than conventional therapy lasting 12 wk or even more than 1 year, produced therapeutic effects similar to those achieved by IFN-alpha or pegylated-IFN-alpha (peg-IFN). Fewer adverse effects, greater efficacy, and a shorter treatment period led to an improvement in patients' quality of life. IFN-beta is administered intravenously, whereas IFN-alpha is administered intramuscularly or subcutaneously. Because both interferons are known to bind to an identical receptor and exert antiviral effects through intracellular signal transduction, the excellent results of IFN-beta found in this study may be attributed to the multiple doses allowed by the intravenous route.
AIM: To investigate the therapeutic efficacy of short-term, multiple daily dosing of intravenous interferon (IFN) in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. METHODS:IFN-beta was intravenously administered at a total dose of 102 million international units (MIU) over a period of 28 d in 26 patients positive for HBeAg and HBV-DNA. IFN-beta was administered at doses of 2 MIU and 1 MIU on d 1, 3 MIU twice daily from d 2 to d 7, and 1 MIU thrice daily from d 8 to d 28. Patients were followed up for 24 wk after the end of treatment. RESULTS: Six months after the end of the treatment, loss of HBV-DNA occurred in 13 (50.0%) of the 26 patients, loss of HBeAg in 9 (34.6%), development of anti-HBe in 10 (38.5%), HBeAg seroconversion in 8 (30.8%), and normalization of alanine aminotransferase (ALT) levels in 11 (42.0%). CONCLUSION: This 4-wk long IFN-beta therapy, which was much shorter than conventional therapy lasting 12 wk or even more than 1 year, produced therapeutic effects similar to those achieved by IFN-alpha or pegylated-IFN-alpha (peg-IFN). Fewer adverse effects, greater efficacy, and a shorter treatment period led to an improvement in patients' quality of life. IFN-beta is administered intravenously, whereas IFN-alpha is administered intramuscularly or subcutaneously. Because both interferons are known to bind to an identical receptor and exert antiviral effects through intracellular signal transduction, the excellent results of IFN-beta found in this study may be attributed to the multiple doses allowed by the intravenous route.
Authors: N W Leung; C L Lai; T T Chang; R Guan; C M Lee; K Y Ng; S G Lim; P C Wu; J C Dent; S Edmundson; L D Condreay; R N Chien Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: E Orito; T Ichida; H Sakugawa; M Sata; N Horiike; K Hino; K Okita; T Okanoue; S Iino; E Tanaka; K Suzuki; H Watanabe; S Hige; M Mizokami Journal: Hepatology Date: 2001-09 Impact factor: 17.425
Authors: S W Schalm; J Heathcote; J Cianciara; G Farrell; M Sherman; B Willems; A Dhillon; A Moorat; J Barber; D F Gray Journal: Gut Date: 2000-04 Impact factor: 23.059
Authors: Patrick Marcellin; Ting-Tsung Chang; Seng Gee Lim; Myron J Tong; William Sievert; Mitchell L Shiffman; Lennox Jeffers; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart Journal: N Engl J Med Date: 2003-02-27 Impact factor: 91.245